The Department of Justice reclassified medical cannabis from Schedule I to Schedule III on April 23, creating a new federal framework for research, banking, taxation, and cross-border trade.
What changed and why it matters – Classification: The DOJ order, signed by acting Attorney General Todd Blanche, moved medical cannabis out of Schedule I (the category that includes heroin and psilocybin) into Schedule III. That reclassification removes the blanket federal illegality for state-licensed medical operations that register with the DEA and comply with federal rules. – Legal effect: State-licensed medical operators that complete DEA registration can operate without violating federal criminal statutes tied to Schedule I. That status change also affects federal tax treatment: firms that register under the new Schedule III designation should no longer face the full scope of Internal Revenue Code section 280E, which now bars many business expense deductions for Schedule I and II sellers. – Research access: Researchers may obtain cannabis from state-licensed dispensaries and growers rather than relying on a small set of federally approved suppliers. The order removes some administrative barriers that limited studies comparing consumer products to research-grade samples.
Pending actions and outstanding questions – Administrative hearing: The DEA has scheduled an administrative hearing for June 29 to address rescheduling implementation. The hearing will focus on operational rules, registration protocols, and how federal agencies will coordinate. – Registration details: The order allows medical cannabis businesses to register with the DEA, but the agency has not yet released step-by-step registration guidance. It remains unclear whether operators holding dual medical and adult-use (recreational) licenses will qualify for federal protections when they sell recreational products. – Tax and banking: Tax relief from 280E depends on IRS interpretation and enforcement. Banks and credit unions will wait for explicit regulatory guidance or safe-harbor language before extending services widely to cannabis businesses.
Federal legislation and research funding Days before the DOJ order, Rep. Dina Titus (D-NV) and Rep. Ilhan Omar (D-MN) reintroduced the Higher Education Marijuana Act to expand federally funded cannabis research programs. The bill targets university research grants and aims to create standardized research channels. The DOJ order and the bill operate in parallel: the DOJ reduces regulatory barriers to research by changing scheduling, while the bill seeks to increase funding and institutional support.
Practical impacts for Nevada – Market structure: Nevada issues combined medical and adult-use licenses. Under the DOJ order, strictly medical operations that register with the DEA would no longer be federally illegal. That legal distinction creates pressure on Nevada regulators and gaming authorities to revisit rules that bar gaming licensees from co-locating cannabis businesses. – Tourist access and the 1,500-foot rule: Nevada law requires a minimum 1,500-foot separation between gaming establishments and cannabis retail in large counties. Nevada receives roughly 42 million visitors per year. Industry analysts estimate the state lost millions in potential tax revenue by limiting cannabis retail access for tourists; the market reached $1 billion in 2020 and is currently about $750 million annually. Moving medical cannabis to Schedule III may increase arguments to relax proximity restrictions, since federal illegality no longer provides the same legal rationale for exclusion. – Interstate and international trade: For the first time in U.S. history, the Schedule III designation opens a federal pathway for importing and exporting cannabis for medical purposes, subject to DEA permit regimes and international treaty obligations. That change could connect Nevada producers with international markets that have fully federal regulatory systems, such as Canada.
Research and clinical implications – Product relevance: Allowing researchers to source products from state-licensed markets addresses a longstanding complaint: federally supplied cannabis often differs in potency and formulation from what consumers use. Researchers expect improved external validity for clinical trials and observational studies. – Timeline and scale: While the schedule change reduces paperwork and supplier constraints, investigators still need DEA registration and institutional approvals. Universities and private labs that already met strict protocol requirements will likely expand studies faster than newer entrants.
Legal and international constraints – Treaty obligations: The United States remains a signatory to the United Nations Single Convention on Narcotic Drugs, which constrains scheduling decisions. DOJ staff and Justice Department lawyers crafted the order to comply with treaty language while changing domestic classification for medical uses. – Plant vs. compounds: The Controlled Substances Act typically schedules compounds rather than whole plants. Cannabis contains dozens of cannabinoids and non-intoxicating compounds; resolving how federal law treats whole-plant products versus isolated compounds will require further regulatory and possibly legislative action.
Outlook and uncertainties The DOJ order removes a major federal barrier for medical cannabis, but it does not legalize adult-use cannabis at the federal level. Key next steps include DEA registration rules, IRS guidance on 280E deductions, banking policy updates, and the June 29 administrative hearing. If state regulators and federal agencies align, Nevada’s medical market could expand, researchers could access more representative products, and international trade could begin under permit systems. Policymakers will have to decide whether to extend protections to mixed-license operators and how to reconcile state-level dual markets with federal medical-only classification.
Bottom line: The April 23 rescheduling changes federal treatment of medical cannabis, creates measurable tax and research pathways, and raises concrete policy questions for Nevada about retail access, co-location with gaming, and participation in international trade. Implementation details over the next months will determine how fast businesses, banks, and researchers adapt.
